(lp0
S'Novelion Therapeutics Reports Preliminary Fourth Quarter &amp; Full Year 2016 ... GlobeNewswire  - Mar 15, 2017 VANCOUVER, British Columbia, March 15, 2017  -- Novelion Therapeutics Inc.  , a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases ... Pro forma net ...Novelion Therapeutics Inc.  Files An 8-K Results of Operations ... - Market ExclusiveNovelion Therapeutics reports 4Q loss - Yahoo Finance'
p1
aS'Novelion Therapeutics Observes Rare Disease Day GlobeNewswire  - Feb 28, 2017 28, 2017  -- Novelion Therapeutics Inc.  , a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced today its alliance with the National ...'
p2
aS'Novelion Therapeutics  Lomitapide Patents Affirmed with Favorable IPR ... StreetInsider.com - Mar 7, 2017 Novelion Therapeutics Inc.  today announced that the United States Patent Trial and Appeal Board  issued a written decision in an Inter Partes Review proceeding affirming the patentability of all claims on U.S. 7,932,268 and U.S.&nbsp;...Novelion prevails in challenge to lomitapide patents - Seeking AlphaNovelion Therapeutics Inc.  Files An 8-K Other Events - Market Exclusive'
p3
aS'Novelion Therapeutics to Announce Preliminary Fourth Quarter and Full Year ... GlobeNewswire  - Mar 13, 2017 VANCOUVER, British Columbia, March 13, 2017  -- Novelion Therapeutics Inc.  , a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today&nbsp;...Zacks: Novelion Therapeutics Inc  Given Average Rating of Buy by ... - Chaffey Breeze'
p4
aS'Novelion Therapeutics Announces Presentation at the 29th Annual ROTH Conference GlobeNewswire  - Mar 8, 2017 VANCOUVER, British Columbia and CAMBRIDGE, Mass., March 08, 2017  -- Novelion Therapeutics, Inc.  , a biopharmaceutical company dedicated to developing new standards of care for individuals living&nbsp;...'
p5
aS'Fortress Biotech Forms New Subsidiary, Cyprium Therapeutics, Inc., to Develop ... Yahoo Finance - Mar 14, 2017 NEW YORK, March 14, 2017  -- Fortress Biotech, Inc.  today announced the launch of a new subsidiary, Cyprium Therapeutics, Inc. , to develop novel therapies for the treatment of Menkes disease and related copper ... to ...'
p6
aS'The Brokerages Anticipate Novelion Therapeutics Inc  to Announce ($0.50 ... Petro Global News 24 - Mar 15, 2017 Shares of Novelion Therapeutics Inc   have earned an average broker rating score of 2.00  from the two brokers that cover the stock, Zacks Investment Research reports.'
p7
aS"Flexion Therapeutics: Novel Knee Osteoarthritis Therapy With Upcoming Catalyst Seeking Alpha - Feb 24, 2017 The company's flagship product candidate, Zilretta is an injectable, extended-release, intra-articular formulation of triamcinolone acetonide, a corticosteroid that is being developed for the treatment of patients with knee osteoarthritis."
p8
aS'Analysts Anticipate Novelion Therapeutics Inc.  to Post  EPS The Cerbat Gem - Feb 19, 2017 Novelion Therapeutics logo Novelion Therapeutics Inc.   has been assigned an average broker rating score of 2.00  from the two brokers that provide coverage for the company, Zacks Investment Research reports.'
p9
aS'Checking on Shares of Novelion Therapeutics Inc.  Piedmont Register - 21 hours ago Checking the Value Composite score for Novelion Therapeutics Inc. , we see that the company has a rank of 81. This falls on a scale from 0 to 100 where a lower score indicated an undervalued company and a higher score would indicate an&nbsp;...'
p10
a.